SynthesisJournal of health, population, and nutrition2026
Serum magnesium and risk of hyperglycemia, type 2 diabetes, and prediabetes: a systematic review and dose-response meta-analysis of observational studies.
Synthesis in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have examined the association between serum magnesium and hyperglycemia, but findings have been inconsistent. Some prospective cohort studies report inverse associations, while others show no significant relationship, and cross-sectional studies have yielded mixed effect sizes. This systematic review and dose-response meta-analysis examines the association between serum magnesium and hyperglycemia.
methodsA comprehensive and systematic search was undertaken utilizing PubMed, Scopus, ISI Web of Science, and Google Scholar, extending up to January 2026. Epidemiologic studies presenting relative risks or odds ratios with 95% confidence intervals regarding serum magnesium and hyperglycemia, type 2 diabetes mellitus (T2DM), and prediabetes were included. The GRADE approach was utilized to evaluate the body of evidence.
resultsA total of 24 studies (7 cohorts, 16 cross-sectional, 2 cross-sectional analyses of cohort baseline data, and 1 case-control) were included. In cohort studies including 46,190 participants and 4,330 cases, negative associations were observed in the highest versus lowest category of serum magnesium with hyperglycemia (RR = 0.67; 95%CI: 0.51, 0.78) and T2DM (RR = 0.67; 95%CI: 0.56, 0.82); this relation was not significant in the case of prediabetes (RR = 0.69; 95%CI: 0.42, 1.02). In non-cohort studies with 40,834 participants and 8,161 cases, reductions in odds were observed for hyperglycemia (OR = 0.43, 95%CI: 0.32, 0.57), T2DM (OR = 0.34, 95%CI: 0.24, 0.46), and prediabetes (OR = 0.53, 95%CI: 0.36, 0.76). In addition, each 0.20 mmol/L increase in serum magnesium level was associated with lower risk of T2DM (RR = 0.92; 95%CI: 0.87, 0.97) in cohort studies and lower odds of hyperglycemia (OR = 0.79; 95%CI: 0.72, 0.86) and T2DM (OR = 0.77; 95%CI: 0.69, 0.87) in cross-sectional studies. In non-linear dose-response analysis, increasing serum magnesium concentration from deficient to sufficient values (> 0.85 mmol/L) was associated with a decreasing trend in hyperglycemia and T2DM risk.
conclusionThere were significant inverse dose-response associations between serum magnesium and hyperglycemia and T2DM. The association with prediabetes was weak and uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.